MDT-AP-0596
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 21.96
- age_years
- 12
- sex
- M
- new_clusters
- C3
- umap1_2d
- 4.978018336
- umap2_2d
- 4.391635397
- umap1_3d
- 2.912839614
- umap2_3d
- -2.35297651
- umap3_3d
- -3.745221761
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.320
- DNA_REPAIR+0.290
- PROTEIN_SECRETION+0.210
- MYC_TARGETS_V2+0.200
- PI3K_AKT_MTOR_SIGNALING+0.200
- PEROXISOME+0.180
- UNFOLDED_PROTEIN_RESPONSE+0.130
- ADIPOGENESIS+0.100
- NOTCH_SIGNALING+0.100
- HEME_METABOLISM+0.090
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.470
- ANGIOGENESIS-0.350
- COAGULATION-0.280
- KRAS_SIGNALING_DN-0.260
- IL6_JAK_STAT3_SIGNALING-0.250
- ALLOGRAFT_REJECTION-0.240
- MYC_TARGETS_V1-0.240
- INFLAMMATORY_RESPONSE-0.230
- ESTROGEN_RESPONSE_LATE-0.220
- TNFA_SIGNALING_VIA_NFKB-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1362 | Med | Medulloblastoma | 0.859 |
| 2 | MDT-AP-0544 | Med | Medulloblastoma | 0.831 |
| 3 | MDT-AP-0574 | Med | Medulloblastoma | 0.830 |
| 4 | MDT-AP-1357 | Med | Medulloblastoma | 0.826 |
| 5 | MDT-AP-1365 | Med | Medulloblastoma | 0.820 |
| 6 | MDT-AP-0604 | Med | Medulloblastoma | 0.814 |
| 7 | MDT-AP-0119 | Med | Medulloblastoma | 0.800 |
| 8 | MDT-AP-0382 | Med | Medulloblastoma | 0.772 |
| 9 | MNG975 | — | — | 0.758 |
| 10 | MNG892 | — | — | 0.757 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.180 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.130 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.030 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |